Zobrazeno 1 - 10
of 110
pro vyhledávání: '"Y Gonzalez-Lama"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
R M Saiz Chumillas, L Alba, Y Gonzalez-Lama, B Velayos, P Suarez, C Maroto-Martin, A Nuñez, L Hernandez, L Relea, L Fernandez-Salazar, M Sierra-Ausin, J Barrio, F Muñoz, L Arias, B Sicilia
Publikováno v:
Journal of Crohn's and Colitis. 16:i211-i213
Background The 21st century has witnessed advances in endoscopic surveillance technology such as high-definition imaging and virtual or dye-based chromoendoscopy, which have led to increased detection of dysplasia. It is unknown the rates of new dysp
Autor:
Y Gonzalez Lama, E Ricart, D Carpio, G Bastida, D Ceballos, D Ginard, I Marín-Jimenéz, L Menchén, F Muñoz
Publikováno v:
Journal of Crohn's and Colitis. 17:i782-i783
Background Over the last years significant advances have arisen in CD. New therapies with different mechanisms of action have been approved for the management of Crohn’s disease (CD). However, there is limited evidence on optimal positioning of age
Autor:
Y. Gonzalez Lama, I Omella Usieto, V Matallana Royo, P Bella del Castillo, I. El Hajra Martinez, M I Vera Mendoza, E. Santos Perez, R De Lucas Téllez de Meneses, B Menchen Viso, B. Ruiz Antoran, M I Calvo Moya, M González Rodriguez, I Gonzalez Partida
Publikováno v:
Journal of Crohn's and Colitis. 15:S507-S509
Background Adalimumab (ADA) intensification is recommended for inadequate or loss of response in inflammatory bowel disease (IBD) patients. A new presentation of ADA 80mg administered every other week (eow) has been approved as an alternative to ADA
Autor:
C Novella, E Vispo, María García, A Gutiérrez Casbas, I Bastón Rey, C Dueñas Sadornil, J Martínez Cadilla, E Iyo, O. Merino Ochoa, M Cabelo, J González García, C Quílez Ivorra, F Argüelles, Javier P. Gisbert, B David, Jordi Gordillo, Mara Charro, S Rubio Iturria, M. Barreiro-de Acosta, P Ramírez de la Piscina, E. Iglesias Flores, B Velayos Jiménez, E Hinojosa, P Martínez Montiel, M Chaparro, M Boscá-Watts, Francisco Javier Bermejo, José María Huguet, Y. Gonzalez Lama, J M Vázque morón, A I Muñagorri Santos, V M Amo, P Fradejas Salazar, A Núñez Ortiz, M D Martín Arranz, Daniel Ginard, L Ramos, M T Diz-Lois Palomares, E Fernández-Salgado, Maite Arroyo
Publikováno v:
Journal of Crohn's and Colitis. 15:S299-S301
Background Crohn′s disease (CD) is a progressive inflammatory bowel disease that can lead to complications such as strictures or penetrating disease, and ultimately surgery, representing a complex clinical challenge in the care of patients. We aime
Autor:
P Ramírez de la Piscina, O. Merino Ochoa, C Quílez Ivorra, E Iyo, Maite Arroyo, Javier P. Gisbert, A Gutiérrez Casbas, David Busquets, C Novella, M. Barreiro-de Acosta, E. Iglesias Flores, Daniel Ginard, B Velayos Jiménez, J M Vázquez Morón, P Fradejas Salazar, A Núñez Ortiz, María García, I Bastón Rey, V M Amo, F Argüelles, M Chaparro, M Boscá-Watts, Francisco Javier Bermejo, Mara Charro, C Dueñas Sadornil, S Rubio Iturria, E Vispo, Jordi Gordillo, M D Martín Arranz, J Martínez Cadilla, A I Muñagorri Santos, J González García, E Hinojosa, P Martínez Montiel, M. E. Cabello, José María Huguet, Y. Gonzalez Lama, M T Diz-Lois Palomares, E Fernández-Salgado, L Ramos
Publikováno v:
Journal of Crohn's and Colitis. 15:S489-S490
Background Whether to use biologic treatment for inflammatory bowel disease as monotherapy or in combination with immunosuppressives has been a matter of debate in the last years. We aimed to evaluate if immunosuppressants influenced the retention ra
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
P Bella del Castillo, Y. Gonzalez Lama, M I Vera Mendoza, R De Lucas Téllez de Meneses, V Matallana Royo, B Menchen Viso, I Gonzalez Partida, I Omella Usieto, M I Calvo Moya, M González Rodriguez
Publikováno v:
Journal of Crohn's and Colitis. 14:S464-S465
Background Current therapeutic goals in Crohn’s disease (CD) include not only the mere absence of symptoms but also the objective resolution of macroscopic lesions, so-called deep remission (DR), which has been related to better outcomes. DR is usu
Autor:
Nikolas Plevris, R Harris, V Domislović, Zeljko Krznaric, S. Shaji, Y. Gonzalez Lama, R. Weishof, David Drobne, Glen A. Doherty, Frank Hoentjen, Stephan R. Vavricka, Darragh Storan, Zuzana Zelinkova, M. Barrero de Acosta, Claire Liefferinckx, A Bar-Gil Shitrit, Triana Lobaton Ortega, Marie J. Pierik, Uri Kopylov, Sally Myers, Denis Franchimont, D. De Marco, Marie Truyens, A Cremer, Charlie W. Lees, Eran Zittan, Vince B. C. Biemans, Cyrielle Gilletta, Fabiana Castiglione, Nicola Imperatore, Jurij Hanzel, Waqqas Afif, I. Baston-Rey, Shomron Ben-Horin
Publikováno v:
Journal of Crohn's and Colitis. 14:S111-S112
Background Ustekinumab (UST) is an effective agent for induction and maintenance of response and remission in Crohn’s disease (CD). In addition to randomised controlled trials, an abundance of real-world evidence is available as well, suggesting th